ES2530941T3 - Tratamiento y prevención de infección por el VIH - Google Patents
Tratamiento y prevención de infección por el VIH Download PDFInfo
- Publication number
- ES2530941T3 ES2530941T3 ES10762626T ES10762626T ES2530941T3 ES 2530941 T3 ES2530941 T3 ES 2530941T3 ES 10762626 T ES10762626 T ES 10762626T ES 10762626 T ES10762626 T ES 10762626T ES 2530941 T3 ES2530941 T3 ES 2530941T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- prevention
- hiv infection
- additional agent
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- JORVRJNILJXMMG-OLNQLETPSA-N brecanavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=C2OCOC2=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C(C=C1)=CC=C1OCC1=CSC(C)=N1 JORVRJNILJXMMG-OLNQLETPSA-N 0.000 abstract 1
- 229950009079 brecanavir Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000010255 intramuscular injection Methods 0.000 abstract 1
- 239000007927 intramuscular injection Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000008092 positive effect Effects 0.000 abstract 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical group N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 1
- 229960000311 ritonavir Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El uso de una formulación parenteral que comprende una cantidad antiviralmente eficaz de brecanavir o una sal de adición de ácido farmacéuticamente aceptable del mismo, y un vehículo, sin un agente adicional que tenga un efecto positivo sobre el metabolismo del fármaco y/o la farmacocinética en cuanto a mejorar la biodisponibilidad, en el que el agente adicional es ritonavir para la fabricación de un medicamento para el tratamiento de un sujeto infectado por el VIH, en el que la formulación va a administrarse por inyección subcutánea o intramuscular intermitentemente en un intervalo de tiempo que está en el intervalo de dos semanas a un año.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09170916 | 2009-09-22 | ||
PCT/EP2010/063930 WO2011036159A2 (en) | 2009-09-22 | 2010-09-22 | Treatment and prevention of hiv infection |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2530941T3 true ES2530941T3 (es) | 2015-03-09 |
Family
ID=41466671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10762626T Active ES2530941T3 (es) | 2009-09-22 | 2010-09-22 | Tratamiento y prevención de infección por el VIH |
Country Status (17)
Country | Link |
---|---|
US (1) | US20120201868A1 (es) |
EP (1) | EP2480220B1 (es) |
JP (1) | JP5897465B2 (es) |
KR (2) | KR101845811B1 (es) |
CN (1) | CN102573815B (es) |
AU (1) | AU2010299959B2 (es) |
BR (1) | BR112012006345A2 (es) |
CA (1) | CA2774750C (es) |
DK (1) | DK2480220T3 (es) |
ES (1) | ES2530941T3 (es) |
HK (1) | HK1174256A1 (es) |
HR (1) | HRP20150192T1 (es) |
MX (1) | MX2012003424A (es) |
PL (1) | PL2480220T3 (es) |
RU (1) | RU2569058C2 (es) |
WO (1) | WO2011036159A2 (es) |
ZA (1) | ZA201202070B (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020358156B2 (en) * | 2019-10-01 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | Method for treating HIV with cabotegravir and rilpivirine |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
AR031520A1 (es) | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
US7220768B2 (en) * | 2003-02-11 | 2007-05-22 | Wyeth Holdings Corp. | Isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus |
CN103877091A (zh) * | 2006-01-20 | 2014-06-25 | 泰博特克药品有限公司 | 用tcm278对hiv感染进行的长期治疗 |
SI2175857T1 (sl) * | 2007-07-12 | 2014-01-31 | Janssen R&D Ireland | Kristalna oblika (E) 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino) 2-pirimidinil)amino)benzonitrila |
-
2010
- 2010-09-22 AU AU2010299959A patent/AU2010299959B2/en not_active Ceased
- 2010-09-22 BR BR112012006345-6A patent/BR112012006345A2/pt not_active Application Discontinuation
- 2010-09-22 JP JP2012529305A patent/JP5897465B2/ja active Active
- 2010-09-22 ES ES10762626T patent/ES2530941T3/es active Active
- 2010-09-22 PL PL10762626T patent/PL2480220T3/pl unknown
- 2010-09-22 EP EP10762626.9A patent/EP2480220B1/en active Active
- 2010-09-22 CA CA2774750A patent/CA2774750C/en active Active
- 2010-09-22 US US13/497,719 patent/US20120201868A1/en not_active Abandoned
- 2010-09-22 RU RU2012116070/15A patent/RU2569058C2/ru active
- 2010-09-22 KR KR1020177036213A patent/KR101845811B1/ko active IP Right Grant
- 2010-09-22 CN CN201080042909.3A patent/CN102573815B/zh active Active
- 2010-09-22 MX MX2012003424A patent/MX2012003424A/es active IP Right Grant
- 2010-09-22 DK DK10762626.9T patent/DK2480220T3/en active
- 2010-09-22 KR KR1020127008150A patent/KR101811314B1/ko active IP Right Grant
- 2010-09-22 WO PCT/EP2010/063930 patent/WO2011036159A2/en active Application Filing
-
2012
- 2012-03-20 ZA ZA2012/02070A patent/ZA201202070B/en unknown
-
2013
- 2013-01-29 HK HK13101244.7A patent/HK1174256A1/xx not_active IP Right Cessation
-
2015
- 2015-02-19 HR HRP20150192AT patent/HRP20150192T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CA2774750A1 (en) | 2011-03-31 |
ZA201202070B (en) | 2013-08-28 |
EP2480220B1 (en) | 2014-11-19 |
CN102573815A (zh) | 2012-07-11 |
CN102573815B (zh) | 2015-09-30 |
HK1174256A1 (en) | 2013-06-07 |
JP2013505224A (ja) | 2013-02-14 |
WO2011036159A2 (en) | 2011-03-31 |
KR101811314B1 (ko) | 2017-12-26 |
CA2774750C (en) | 2017-11-28 |
KR20170141825A (ko) | 2017-12-26 |
JP5897465B2 (ja) | 2016-03-30 |
WO2011036159A3 (en) | 2011-11-24 |
RU2012116070A (ru) | 2013-10-27 |
US20120201868A1 (en) | 2012-08-09 |
KR101845811B1 (ko) | 2018-05-18 |
EP2480220A2 (en) | 2012-08-01 |
AU2010299959B2 (en) | 2016-07-21 |
RU2569058C2 (ru) | 2015-11-20 |
BR112012006345A2 (pt) | 2020-08-11 |
MX2012003424A (es) | 2012-05-08 |
KR20120093850A (ko) | 2012-08-23 |
DK2480220T3 (en) | 2015-02-23 |
PL2480220T3 (pl) | 2015-10-30 |
HRP20150192T1 (hr) | 2015-04-10 |
AU2010299959A1 (en) | 2012-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
HRP20180007T1 (hr) | Formulacija koja sadrži gemcitabin-predlijek | |
CL2016002132A1 (es) | Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo. | |
UY37998A (es) | Agentes antivirales contra la hepatitis b | |
AR059097A1 (es) | Tratamiento a largo plazo de la infeccion por vih | |
CL2021002747A1 (es) | Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020) | |
MD4736C1 (ro) | Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia | |
PE20120713A1 (es) | Composiciones sublinguales de dexmedetomidina y metodos para su uso | |
BR112015013695A2 (pt) | composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv | |
WO2013123215A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
AR101674A1 (es) | Uso de un compuesto tricíclico que contiene nitrógeno | |
FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
MD3651736T2 (ro) | Formulări cu acțiune prelungită | |
RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
UY31826A (es) | Compuesto peptídico y su uso | |
ES2530941T3 (es) | Tratamiento y prevención de infección por el VIH | |
AR082806A1 (es) | Composicion farmaceutica estable | |
EP2606885A4 (en) | "RENESSANS" MEDICINAL PREPARATION WITH ANTIBACTERIAL, ANTI-ULCER AND IMMUNOMODULATORY ACTION | |
WO2014129884A3 (en) | Composition with inhibitory effect on viral integrase activity |